Immuron CEO Steven Lydeamore to present at Peak Sky High
May 31, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief...
Immuron Board Changes
May 31, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston...
Immuron Limited to Present at the Emerging Growth Conference
May 07, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual...
Immuron Director Resignation
May 03, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen...
Immuron to host Live Virtual Event
April 15, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron Travelan® sales continued strong growth
April 10, 2024 06:00 ET
|
Immuron Limited
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter ...
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
March 07, 2024 06:00 ET
|
Immuron Limited
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron achieves record Travelan® sales
February 13, 2024 06:00 ET
|
Immuron Limited
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
February 08, 2024 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...